OXiGENE Reports Year-End 2008 Cash, Cash Equivalents and Marketable Securities Balance and Provides Corporate Update and Outlook for 2009
February 26, 2009 16:00 ET
|
Mateon Therapeutics
WALTHAM, Mass., Feb. 26, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE Announces Fourth Quarter and Fiscal 2008 Earnings Conference Call and Webcast
February 19, 2009 02:00 ET
|
Mateon Therapeutics
WALTHAM, Mass., Feb. 19, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye...
OXiGENE to Present At BIO CEO and Investor Conference On February 9, 2009
February 02, 2009 16:00 ET
|
Mateon Therapeutics
WALTHAM, Mass., Feb. 2, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye...
Drug Development Experts Nicole Onetto, M.D., and Eric Rowinsky, M.D. Join Symphony ViDA Board of Directors
January 12, 2009 02:19 ET
|
Mateon Therapeutics
WALTHAM, Mass., Jan. 12, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye...
OXiGENE Stockholders Approve Share Issuance to Symphony Capital
December 09, 2008 16:00 ET
|
Mateon Therapeutics
WALTHAM, Mass., Dec. 9, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE Receives NASDAQ Notification
November 14, 2008 16:00 ET
|
Mateon Therapeutics
WALTHAM, Mass., Nov. 14, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported that...
OXiGENE to Present at Rodman and Renshaw, Lazard Healthcare Conferences
November 06, 2008 02:04 ET
|
Mateon Therapeutics
WALTHAM, Mass., Nov. 6, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye...
OXiGENE Updates Progress and Reports Third Quarter 2008 Financial Results
November 05, 2008 02:25 ET
|
Mateon Therapeutics
WALTHAM, Mass., Nov. 5, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye...
OXiGENE Announces Third Quarter 2008 Earnings Conference Call and Webcast
October 30, 2008 02:00 ET
|
Mateon Therapeutics
WALTHAM, Mass., Oct. 30, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye...
OXiGENE Reports Positive Phase 2 Interim Results in Platinum-Resistant Ovarian Cancer for Lead Vascular Disrupting Agent, ZYBRESTAT(tm)
October 27, 2008 02:03 ET
|
Mateon Therapeutics
WALTHAM, Mass., Oct. 27, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye...